BioOncology Genentech Inc. / Oncology Biostatistics Genentech Inc. / M.D. / Hematology/Oncology Genentech Inc. / Genentech Inc. / Sponsor Presentation Introduction Genentech Inc. / /
Facility
Breast Medical Oncology The University of Texas / /
IndustryTerm
treatment of HER2-negative metastatic breast cancer / supplemental biologic license applications / /
MedicalCondition
HER2-negative breast cancer / HER2 negative breast cancer / metastatic breast cancer / HER2-negative metastatic breast cancer / /
MedicalTreatment
chemotherapy / /
Organization
office of Oncology Drug Products / office of New Drugs / Division of Biologic Oncology Products / Roche Group Measures and Magnitude of Avastin Progression Free Survival / Roche Group Efficacy and Safety Results See Phan / Roche Group HER2-Negative Metastatic Breast Cancer and Avastin / FDA / FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation / Research Oncologic Drugs Advisory Committee / University of Texas / /
Person
Opening Remarks Richard Pazdur / Lee Pai-Scherf / Nicole Vesely / Wyndham Wilson / Sandra Horning / See Phan / Concluding Remarks Sandra Horning / James Reimann / /
Position
Director / Member of the Roche Group / Vice President / Medical Director / Chair / Medical Officer / Professor and Chairman / Department of Breast Medical / Federal Official / /
FOOD AND DRUG ADMINISTRATION